GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OCSE:COLO B) » Definitions » Shares Outstanding (EOP)

Coloplast AS (OCSE:COLO B) Shares Outstanding (EOP) : 225 Mil (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Coloplast AS Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Coloplast AS's shares outstanding for the quarter that ended in Sep. 2024 was 225 Mil.

Coloplast AS's quarterly shares outstanding increased from Jun. 2024 (225 Mil) to Sep. 2024 (225 Mil). It means Coloplast AS issued new shares from Jun. 2024 to Sep. 2024 .

Coloplast AS's annual shares outstanding increased from Sep. 2023 (225 Mil) to Sep. 2024 (225 Mil). It means Coloplast AS issued new shares from Sep. 2023 to Sep. 2024 .


Coloplast AS Shares Outstanding (EOP) Historical Data

The historical data trend for Coloplast AS's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS Shares Outstanding (EOP) Chart

Coloplast AS Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 212.68 212.80 212.31 224.66 225.34

Coloplast AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.66 224.83 225.04 225.04 225.34

Competitive Comparison of Coloplast AS's Shares Outstanding (EOP)

For the Medical Instruments & Supplies subindustry, Coloplast AS's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Coloplast AS's Shares Outstanding (EOP) falls into.



Coloplast AS Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Coloplast AS  (OCSE:COLO B) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Coloplast AS Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Coloplast AS's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Traded in Other Exchanges
Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

No Headlines